CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy

CREATE Medicines Inc., a clinical-stage biotechnology company pioneering in vivo multi-immune programming, today announced ...

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of ...

Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients ...

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.